HMPAO SPECT in Parkinson's disease (PD) with major depression (MD) before and after antidepressant treatment.
Previously we suggested that major depression (MD) in Parkinson's disease (PD) could be an indication of a more advanced and widespread neurodegenerative process, as PD symptoms were more severe in those with depression. We also found a different antidepressant response with SSRI medication in PD patients with depression compared to depressed patients without PD. This indicates diverse underlying pathophysiological mechanisms. Investigations using single-photon emission computed tomography (SPECT), measuring regional cerebral blood flow (rCBF), may contribute to enlighten the neurobiological substrates linked to depressive symptoms. SPECT was performed in order to compare rCBF in MD patients with and without PD. The study included 11 MD patients with PD, 14 non-depressed PD patients and 12 MD patients without PD. All patients were followed for 12 weeks with repeated evaluation of depressive as well as PD symptoms. Anti-Parkinsonian treatment remained unchanged during the study. Antidepressant treatment with SSRI (citalopram) was given to all patients with MD. SPECT was performed before and after 12 weeks of antidepressant treatment. rCBF was found to differ between PD patients with and without MD, as well as between MD patients with and without PD, both at baseline and concerning the response to treatment with SSRI (citalopram). In patients with PD the rCBF was found to be decreased in preoccipital and occipital regions, a finding more common when PD was combined with MD. In summary, larger cortical areas were found to be involved in depressed PD patients, both with hyperactivity (reciprocal to basal degeneration in PD and maybe dopaminergic treatment) and with hypoactivity (probably due to organic lesions leading to hypoperfusion). These observations support our hypothesis that PD combined with MD is an expression of a more advanced and widespread neurodegenerative disorder.
Pålhagen
Sven E
SE
Department of Clinical Neuroscience, Division of Neurology Huddinge, Karolinska Institute, Stockholm, Sweden. sven.palhagen@karolinska.se
Ekberg
Stefan
S
Wålinder
Jan
J
Granérus
Ann-Kathrine
AK
Granerus
Göran
G
D000368:Aged; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D000978:Antiparkinson Agents / Q000627:therapeutic use; D001921:Brain / Q000098:blood supply / Q000000981:diagnostic imaging / Q000187:drug effects; D001931:Brain Mapping; D002560:Cerebrovascular Circulation / Q000187:drug effects; D015283:Citalopram / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010091:Oximes; D010300:Parkinson Disease / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000503:physiopathology; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D013997:Time Factors; D015899:Tomography, Emission-Computed, Single-Photon
D018687:Antidepressive Agents, Second-Generation; D000978:Antiparkinson Agents; D015283:Citalopram; D010091:Oximes; D017367:Selective Serotonin Reuptake Inhibitors; C068296:hexamethylpropyleneamine oxime